全文获取类型
收费全文 | 7972篇 |
免费 | 455篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 75篇 |
儿科学 | 329篇 |
妇产科学 | 224篇 |
基础医学 | 900篇 |
口腔科学 | 130篇 |
临床医学 | 1323篇 |
内科学 | 1262篇 |
皮肤病学 | 126篇 |
神经病学 | 618篇 |
特种医学 | 291篇 |
外科学 | 803篇 |
综合类 | 73篇 |
一般理论 | 12篇 |
预防医学 | 1026篇 |
眼科学 | 107篇 |
药学 | 625篇 |
中国医学 | 13篇 |
肿瘤学 | 550篇 |
出版年
2023年 | 33篇 |
2022年 | 66篇 |
2021年 | 119篇 |
2020年 | 75篇 |
2019年 | 134篇 |
2018年 | 163篇 |
2017年 | 120篇 |
2016年 | 134篇 |
2015年 | 174篇 |
2014年 | 236篇 |
2013年 | 322篇 |
2012年 | 485篇 |
2011年 | 544篇 |
2010年 | 350篇 |
2009年 | 252篇 |
2008年 | 502篇 |
2007年 | 550篇 |
2006年 | 587篇 |
2005年 | 536篇 |
2004年 | 507篇 |
2003年 | 481篇 |
2002年 | 535篇 |
2001年 | 136篇 |
2000年 | 136篇 |
1999年 | 132篇 |
1998年 | 95篇 |
1997年 | 90篇 |
1996年 | 58篇 |
1995年 | 59篇 |
1994年 | 52篇 |
1993年 | 40篇 |
1992年 | 56篇 |
1991年 | 36篇 |
1990年 | 46篇 |
1989年 | 39篇 |
1988年 | 52篇 |
1987年 | 40篇 |
1986年 | 39篇 |
1985年 | 41篇 |
1984年 | 26篇 |
1983年 | 29篇 |
1982年 | 25篇 |
1981年 | 28篇 |
1980年 | 27篇 |
1979年 | 21篇 |
1978年 | 22篇 |
1977年 | 24篇 |
1975年 | 18篇 |
1974年 | 27篇 |
1973年 | 19篇 |
排序方式: 共有8487条查询结果,搜索用时 15 毫秒
91.
Frequency of the ATM IVS10-6T→G variant in Australian multiple-case breast cancer families
下载免费PDF全文
![点击此处可从《Breast cancer research : BCR》网站下载免费的PDF全文](/ch/ext_images/free.gif)
92.
Cara L Frankenfeld Anne McTiernan Erin J Aiello Wendy K Thomas Kristin LaCroix Judy Schramm Stephen M Schwartz Victoria L Holt Johanna W Lampe 《Cancer epidemiology, biomarkers & prevention》2004,13(7):1156-1162
Circulating hormones are associated with mammographic density, an intermediate marker of breast cancer risk. Differences in circulating hormones, including estrone and testosterone, have been observed in premenopausal women based on their capacity to metabolize daidzein, an isoflavone found predominantly in soybeans. Equol and O-desmethylangolensin (O-DMA) are products of intestinal bacterial metabolism of daidzein. There is interindividual variability in the capacity to produce daidzein metabolites; individuals can be equol producers or non-producers and O-DMA producers or non-producers. We tested the hypothesis that daidzein-metabolizing phenotypes are associated with mammographic density. Participants were recruited from among 92 sedentary, postmenopausal women, ages 50 to 75 years, who participated in a 1-year physical activity intervention. Pre-intervention mammographic density was determined using a computer-assisted, gray-scale thresholding technique. Fifty-five of these women consumed supplemental soy protein (>10 mg daidzein/d) for 3 days and collected a first-void urine sample on the fourth day to determine daidzein-metabolizing phenotypes. Equol and O-DMA concentrations were measured using gas chromatography-mass spectrometry. Associations between daidzein-metabolizing phenotypes and percent mammographic density were adjusted for age, maximum adult weight, gravidity, family history of breast cancer, and serum follicle-stimulating hormone and free testosterone concentrations. Mammographic density was 39% lower in equol producers compared with non-producers (P = 0.04). O-DMA producers had mammographic density 69% greater than non-producers (P = 0.05). These results suggest that particular intestinal bacterial profiles are associated with postmenopausal mammographic density, and these associations are not entirely explained by differences in reproductive or anthropometric characteristics or circulating hormones. 相似文献
93.
Douglas S Hawkins Julie R Park Blythe G Thomson Judy L Felgenhauer John S Holcenberg Eduard H Panosyan Vassilios I Avramis 《Clinical cancer research》2004,10(16):5335-5341
PURPOSE: Asparaginase therapy is an important component in the treatment of children with acute lymphoblastic leukemia. Polyethylene glycol-conjugated asparaginase (PEG-ASNase) has significant pharmacological advantages over native Escherichia coli asparaginase. We investigated the pharmacokinetics of PEG-ASNase, presence of antibodies to PEG-ASNase, and concentrations of asparagine in serum and cerebrospinal fluid (CSF) in combination chemotherapy for relapsed pediatric acute lymphoblastic leukemia. EXPERIMENTAL DESIGN: Twenty-eight pediatric patients with relapsed medullary (n = 16) and extramedullary (n = 11) acute lymphoblastic leukemia were enrolled at three pediatric institutions and had at least two serum and CSF samples obtained for analysis. Patients received induction therapy (including PEG-ASNase 2500 IU/m2 intramuscularly weekly on days 2, 9, 16, and 23) and intensification therapy (including PEG-ASNase 2500 IU/m2 intramuscularly once on day 7). Serum samples were obtained weekly during induction and intensification. CSF samples were obtained during therapeutic lumbar punctures during induction and intensification. RESULTS: Weekly PEG-ASNase therapy resulted in PEG-ASNase activity of >0.1 IU/ml in 91-100% of patients throughout induction. During intensification, PEG-ASNase on day 7 resulted in PEG-ASNase activity >0.1 IU/ml in 94% and 80% of patients on days 14 and 21, respectively. Serum and CSF asparagine depletion was observed and maintained during induction and intensification in the majority of samples. PEG-ASNase antibody was observed in only 3 patients. CONCLUSIONS: Intensive PEG-ASNase therapy in the treatment of relapsed acute lymphoblastic leukemia reliably results in high-level serum PEG-ASNase activity, and asparagine depletion in serum and CSF is usually achieved. Incorporation of intensive PEG-ASNase in future trials for recurrent acute lymphoblastic leukemia is warranted. 相似文献
94.
Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. 总被引:4,自引:0,他引:4
Roger J Packer James G Gurney Judy A Punyko Sarah S Donaldson Peter D Inskip Marilyn Stovall Yutaka Yasui Ann C Mertens Charles A Sklar H Stacy Nicholson Lonnie K Zeltzer Joseph P Neglia Leslie L Robison 《Journal of clinical oncology》2003,21(17):3255-3261
PURPOSE: To describe the neurologic and neurosensory deficits in children with brain tumors (BTs), compare incidence of these deficits with that of a sibling control group, and evaluate the factors associated with the development of these deficits. PATIENTS AND METHODS: Detailed questionnaires were completed on 1,607 patients diagnosed between 1970 and 1986 with a primary CNS tumor. Neurosensory and neurologic dysfunctions were assessed and results compared with those of a sibling control group. Medical records on all patients were abstracted, including radiotherapy dose and volume. RESULTS: Seventeen percent of patients developed neurosensory impairment. Relative to the sibling comparison group, patients surviving BTs were at elevated risk for hearing impairments (relative risk [RR], 17.3; P = <.0001), legal blindness in one or both eyes (RR, 14.8; P = <.0001), cataracts (RR, 11.9; P = <.0001), and double vision (RR, 8.8; P = <.0001). Radiation exposure greater than 50 Gy to the posterior fossa was associated with a higher likelihood of developing any hearing impairment. Coordination and motor control problems were reported in 49% and 26%, respectively, of survivors. Children receiving at least 50 Gy to the frontal brain regions had a moderately elevated risk for motor problems (RR, 2.0; P <.05). Seizure disorders were reported in 25% of patients, including 6.5% who had a late first occurrence. Radiation dose of 30 Gy or more to any cortical segment of the brain was associated with a two-fold elevated risk for a late seizure disorder. CONCLUSION: Children surviving BTs are at significant risk for both early and late neurologic or neurosensory sequelae. These sequelae need to be prospectively monitored. 相似文献
95.
Lindon J. Eaves Judy L. Silberg Joanne M. Meyer Hermine H. Maes Emily Simonoff rew Pickles Michael Rutter Chandra A. Reynolds rew C. Heath Kimberly R. Truett Michael C. Neale Marilyn T. Erikson Rolf Loeber John K. Hewitt 《Journal of child psychology and psychiatry, and allied disciplines》1997,38(8):965-980
96.
Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Canadian Medical Association journal》网站下载免费的PDF全文](/ch/ext_images/free.gif)
97.
98.
Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. 总被引:5,自引:0,他引:5
Frederick P Li Jonathan A Fletcher Michael C Heinrich Judy E Garber Stephen E Sallan Clara Curiel-Lewandrowski Anette Duensing Matt van de Rijn Lowell E Schnipper George D Demetri 《Journal of clinical oncology》2005,23(12):2735-2743
PURPOSE: Members of a family with hereditary gastrointestinal stromal tumors (GISTs) and a germline KIT oncogene mutation were evaluated for other potential syndrome manifestations. A tumor from the proband was analyzed to compare features with sporadic GISTs. PATIENTS AND METHODS: Members of a kindred in which six relatives in four consecutive generations comprised an autosomal dominant pattern of documented GISTs and cutaneous lesions underwent physical examination, imaging studies, and germline KIT analysis. A recurrent GIST from the proband was studied using microarray, karyotypic, immunohistochemical, and immunoblotting techniques. RESULTS: In addition to evidence of multiple GISTs, lentigines, malignant melanoma, and an angioleiomyoma were identified in relatives. A previously reported gain-of-function missense mutation in KIT exon 11 (T --> C) that results in a V559A substitution within the juxtamembrane domain was identified in three family members. The proband's recurrent gastric GIST had a 44,XY-14,-22 karyotype and immunohistochemical evidence of strong diffuse cytoplasmic KIT expression without expression of actin, desmin, or S-100. Immunoblotting showed strong expression of phosphorylated KIT and downstream signaling intermediates (AKT and MAPK) at levels comparable with those reported in sporadic GISTs. cDNA array profiling demonstrated clustering with sporadic GISTs, and expression of GIST markers comparable to sporadic GISTs. CONCLUSION: These studies provide the first evidence that gene expression and mechanisms of cytogenetic progression and cell signaling are indistinguishable in familial and sporadic GISTs. Current investigations of molecularly targeted therapies in GIST patients provide opportunities to increase the understanding of features of the hereditary syndrome, and risk factors and molecular pathways of the neoplastic phenotypes. 相似文献
99.
Carl Morrison Michael Radmacher Nehad Mohammed David Suster Herbert Auer Susie Jones Judy Riggenbach Nicole Kelbick Gary Bos Joel Mayerson 《Journal of clinical oncology》2005,23(36):9369-9376
PURPOSE: To identify recurrent regions of genomic gain or loss in chondrosarcoma in a clinically relevant and statistically valid fashion. Materials and METHODS: Array comparative genomic hybridization (CGH) results of 15 frozen tumor samples of high-grade chondrosarcoma for chromosome 8 are presented. A separate subset of 116 cartilaginous tumors with outcome data was used for validation. RESULTS: Array CGH identified gain at 8q24.12-q24.13, the region of the MYC (c-Myc) oncogene, as a frequent change in high-grade chondrosarcoma. In the validation arm of 116 cartilaginous tumors, MYC was frequently amplified in G2 (15%), G3 (20%), and dedifferentiated (21%) chondrosarcomas. No amplification was identified in samples of enchondroma and grade 1 chondrosarcoma. In samples without MYC amplification, polysomy 8 was a frequent finding in grade 1 (18%), grade 2 (31%), grade 3 (80%), and dedifferentiated (29%) chondrosarcomas, but was not found in any samples of enchondroma. MYC protein expression was identified in all samples with amplification, but was also frequent in the remaining samples without amplification or polysomy 8. Kaplan-Meier survival curves for overall survival showed a statistically significant difference for patients with MYC amplification or polysomy 8 (P = .034). Univariate analysis involving Cox proportional hazards models showed that grade (P = .003), polysomy 8 (P = .045), and MYC amplification (P = .053) correlated with shorter overall survival. By multivariate analysis, grade of chondrosarcoma (P = .026) was the only factor to reach statistical significance. CONCLUSION: MYC amplification and polysomy 8 can be used as markers of prognostic importance in chondrosarcoma. Molecular targeting of MYC expression may have therapeutic potential in the future for subsets of chondrosarcoma. 相似文献
100.
Sharon K Krueger Lisbeth K Siddens Sarah R Martin Zhen Yu Clifford B Pereira Erwin T Cabacungan Ronald N Hines Kristin G Ardlie Judy L Raucy David E Williams 《Drug metabolism and disposition》2004,32(12):1337-1340
A polymorphism for the phase I drug-metabolizing enzyme, flavin-containing monooxygenase isoform 2 (FMO2), encoding either truncated inactive protein, FMO2X472 (FMO2.2A), or full-length active enzyme, FMO2Q472 (FMO2.1), is known and exhibits significant interethnic differences in allelic frequency. FMO2 is the major or sole FMO isoform expressed in the lung of most mammals, including nonhuman primates. To date, FMO2.1 has been found only in African-American and Hispanic populations, rendering individuals with this allele subject to drug metabolism that is potentially different from that of the general population. Approximately 26% of African-Americans (n = 180) possess the FMO2*1 allele. In preliminary studies, we initially estimated that 5% of Hispanics (n = 40) have the FMO2*1 allele, but access to large cohorts of individuals of defined national origin has allowed us to determine the occurrence among Mexican-American and Puerto Rican-American groups. We used allele-specific genotyping to detect FMO2*1 from 632 Hispanic individuals, including 280 individuals of Mexican origin and 327 individuals of Puerto Rican origin. Statistical analysis indicated that results from Mexican (five sample sources) and Puerto Rican (three sample sources) samples were consistent with the hypothesis of homogeneity within each group from different sources. Data were subsequently pooled across sources to test for evidence of a difference in occurrence of FMO2*1 between ethnic groups. There was strong evidence (p = 0.0066) that FMO2*1 is more common among Puerto Ricans (7%) than among individuals of Mexican descent (2%). The overall occurrence of FMO2*1 among Hispanics of all origins is estimated to be between 2 and 7%. 相似文献